Published in J Manag Care Pharm on January 14, 2004
Challenges in evaluating the cost-effectiveness of statins. J Manag Care Pharm (2004) 0.75
Determinants of the cost-effectiveness of statins. J Manag Care Pharm (2003) 2.68
Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm (2003) 3.34
Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care (2003) 2.33
Costs of necrotizing enterocolitis and cost-effectiveness of exclusively human milk-based products in feeding extremely premature infants. Breastfeed Med (2011) 2.12
Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis (2004) 1.65
Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther (2004) 1.46
Where's the value in health care? Value Health (2006) 1.45
Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health (2009) 1.43
Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm (2006) 1.26
Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI. Value Health (2009) 1.11
Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program. Value Health (2003) 1.09
Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV. Value Health (2009) 0.98
Where do I send thee? Does physician-ownership affect referral patterns to ambulatory surgery centers? Health Aff (Millwood) (2008) 0.98
Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V. Value Health (2009) 0.96
Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III. Value Health (2009) 0.96
Understanding the underlying drivers of inpatient cost growth: a literature review. Am J Manag Care (2003) 0.96
Effects of ambulatory-care pharmacist consultation on mortality and hospitalization. Am J Manag Care (2003) 0.91
Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid. BMC Pediatr (2013) 0.88
Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs. Am J Geriatr Psychiatry (2011) 0.87
The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro Oncol (2013) 0.87
Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias. Pharmacoepidemiol Drug Saf (2012) 0.85
Costs and benefits of male circumcision. JAMA Pediatr (2013) 0.85
Asthma costs and utilization in a managed care organization. J Allergy Clin Immunol (2008) 0.83
Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States. Pharmacoeconomics (2013) 0.80
A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Opin Pharmacother (2007) 0.79
Appropriate econometric methods for pharmacoeconometric studies of retrospective claims data: an introductory guide. J Manag Care Pharm (2005) 0.79
Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Expert Rev Pharmacoecon Outcomes Res (2015) 0.79
Cost-benefit analysis of in-hospital influenza vaccination of postpartum women. Obstet Gynecol (2012) 0.78
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer (2009) 0.78
Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis. Clin Ther (2012) 0.77
Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S. Gen Dent (2010) 0.76
Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia. PLoS One (2013) 0.76
Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine. CNS Drugs (2005) 0.76
Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data. Health Econ (2012) 0.76
Comparing patient access to pharmaceuticals in the UK and US. Appl Health Econ Health Policy (2006) 0.75
Expensive conditions. Health Aff (Millwood) (2002) 0.75
A six-year study of diagnostic lower extremity imaging practice patterns and outcomes in the Veterans Affairs health care system. Int J Angiol (2008) 0.75
Effects of medicaid on clinical outcomes. N Engl J Med (2013) 0.75
What is more valuable: fenofibrate patents or fenofibrate clinical outcomes? Arch Intern Med (2012) 0.75
Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials. Expert Rev Pharmacoecon Outcomes Res (2014) 0.75
A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments. Pharmacoeconomics (2014) 0.75
Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System. J Manag Care Spec Pharm (2015) 0.75
Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. J Med Econ (2013) 0.75
Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis. CNS Drugs (2015) 0.75
Cost-benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). Vaccine (2013) 0.75